Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape

BACKGROUND: Two new antibody–drug conjugates (ADCs) containing a topoisomerase I inhibitor payload have recently emerged in the breast cancer (BC) treatment landscape. Sacituzumab govitecan-hziy (SG) is a first-in-class anti-trophoblast cell-surface antigen 2 ADC approved for pretreated metastatic t...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, E., Wildiers, H., Neven, P., Punie, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259232/
https://www.ncbi.nlm.nih.gov/pubmed/34225076
http://dx.doi.org/10.1016/j.esmoop.2021.100204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259232/
https://www.ncbi.nlm.nih.gov/pubmed/34225076
http://dx.doi.org/10.1016/j.esmoop.2021.100204

Ejemplares similares